PDCD1 and small cell lung carcinoma: However, a key issue of relevance both in the laboratory and in the clinic is the comparison of these agents on the basis of efficacy and toxicity, and we would like to know if there is a difference in therapeutic blockade between PD‐1 inhibitors plus chemotherapy and PD‐L1 inhibitors plus chemotherapy in the first‐line therapy of patients with ES‐SCLC.